Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Dyne Therapeutics, Inc. (DYN)  
$33.07 0.62 (1.84%) as of 4:30 Fri 6/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 81,110,000
Market Cap: 2.68(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.62 - $35.38
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 21.5
Insider 3/6 Months : 22.1
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 1,714,285 1,714,285 3,583,447
Total Buy Value $0 $29,999,988 $29,999,988 $50,000,022
Total People Bought 0 1 1 3
Total Buy Transactions 0 1 1 3
Total Shares Sold 178,398 5,181,810 5,246,489 5,886,581
Total Sell Value $5,589,780 $124,449,619 $125,087,013 $133,209,946
Total People Sold 5 9 9 9
Total Sell Transactions 14 75 97 117
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 222
  Page 3 of 9  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Atlas Venture Associates Opportunity Ii, Llc 10% Owner   –       –       •   2024-02-23 4 AS $22.70 $848,662 I/I (37,386) 920,843 45%     
   Atlas Venture Associates Opportunity Ii, Llc 10% Owner   –       –       •   2024-02-23 4 AS $22.70 $3,621,603 D/D (159,542) 6,352,562 45%     
   Rhodes Jason P   –       •      –    2024-02-22 4 AS $22.66 $2,704,698 I/I (119,360) 6,512,104 48%     
   Atlas Venture Associates Opportunity Ii, Llc 10% Owner   –       –       •   2024-02-22 4 AS $22.66 $2,704,698 D/D (119,360) 6,512,104 48%     
   Rhodes Jason P   –       •      –    2024-02-21 4 AS $22.44 $4,164,817 I/I (184,501) 6,631,464 47%     
   Atlas Venture Associates Opportunity Ii, Llc 10% Owner   –       –       •   2024-02-21 4 AS $22.44 $4,164,817 D/D (184,501) 6,631,464 47%     
   Atlas Venture Associates Xi, Llc 10% Owner   –       –       •   2024-02-20 4 AS $22.71 $3,852,653 D/D (169,539) 6,815,965 45%     
   Rhodes Jason P   –       •      –    2024-02-20 4 AS $22.71 $3,852,653 I/I (169,539) 6,815,965 45%     
   Atlas Venture Associates Xi, Llc 10% Owner   –       –       •   2024-02-16 4 AS $23.14 $3,765,040 D/D (162,707) 6,985,504 44%     
   Rhodes Jason P   –       •      –    2024-02-16 4 AS $23.14 $3,765,040 I/I (162,707) 6,985,504 44%     
   Atlas Venture Associates Xi, Llc 10% Owner   –       –       •   2024-02-15 4 AS $23.88 $4,249,600 D/D (177,906) 7,148,211 40%     
   Rhodes Jason P   –       •      –    2024-02-15 4 AS $23.88 $4,249,600 I/I (177,906) 7,148,211 40%     
   Farwell Wildon Chief Medical Officer   •       –      –    2024-02-12 4 AS $25.07 $137,710 D/D (5,493) 163,503 36%     
   Brumm Joshua T CEO & President   •       •      –    2024-01-29 4 GD $0.00 $0 D/D 21,500 563,471     -
   Farwell Wildon Chief Medical Officer   •       –      –    2024-01-26 4 AS $25.00 $2,500 D/D (100) 168,996 54%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-01-26 4 AS $24.52 $490,510 D/D (20,000) 143,618 54%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-01-26 4 OE $0.73 $14,600 D/D 20,000 163,618     -
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-01-26 4 AS $24.34 $316,420 D/D (13,000) 124,228 54%     
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-01-26 4 OE $1.03 $13,390 D/D 13,000 137,228     -
   Kersten Dirk   –       •       •   2024-01-09 4 B $17.50 $29,999,988 I/I 1,714,285 1,428,571 0.01 88%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2024-01-04 4 AS $18.13 $769,673 D/D (42,453) 156,806 52%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2024-01-04 4 OE $1.03 $23,354 D/D 22,674 199,259     -
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-01-04 4 AS $18.04 $36,242 D/D (2,009) 143,618 52%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-01-04 4 OE $0.73 $1,467 D/D 2,009 145,627     -
   Brumm Joshua T CEO & President   •       –      –    2024-01-04 4 AS $18.40 $4,045,958 D/D (218,536) 584,971 52%     
  222 Records found
  1  2  3  4  5  6  7  8  9   
  Page 3 of 9
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us